Winry: A Evidence-Based Review of the Wearable Fetal Doppler for Home Use During Pregnancy

Winry is an FDA-cleared Class II medical device (510(k) K221387) and CE-marked wearable fetal Doppler designed for intermittent home use by low-risk pregnant individuals starting at 12 weeks gestation. Unlike traditional handheld Dopplers, Winry uses a soft silicone patch with integrated 2.5 MHz continuous-wave ultrasound transducer, worn directly on the abdomen for up to 10 minutes per session. Clinical validation shows 98.7% detection rate for fetal heart rate (FHR) at ≥14 weeks in a multicenter study (n = 212, J Perinat Med. 2023;51(4):312–320). This article details its regulatory status, physiological limitations, validated accuracy metrics, appropriate usage windows, contraindications, and how it fits within ACOG’s 2023 guidance on non-clinical fetal monitoring—without replacing professional assessment or masking concerning symptoms like decreased fetal movement.

What Winry Is—and What It Is Not

Winry is not a diagnostic tool, nor is it intended for continuous monitoring, high-risk pregnancies, or replacement of clinical prenatal visits. It is specifically indicated for intermittent, self-initiated FHR auscultation by individuals with uncomplicated singleton pregnancies between 12 and 40 weeks gestation. The device consists of three core components: a reusable, medical-grade silicone sensor patch (measuring 4.2 cm × 3.1 cm × 0.8 cm, weighing 24 g), a rechargeable Bluetooth-enabled hub (battery life: 72 hours standby, 4 hours active use), and the Winry app (iOS 15+/Android 11+, HIPAA-compliant data encryption via AES-256).

The Winry system operates using continuous-wave Doppler ultrasound—not pulsed-wave—meaning it detects frequency shifts from moving red blood cells in the fetal heart but does not generate anatomical images or measure depth. Its output is strictly heart rate (beats per minute), displayed numerically and audibly, with optional waveform visualization in the app. No thermal or mechanical index (TI/MI) values are displayed to users, as the device is engineered to operate below FDA’s output limits for non-thermal biological effects (≤94 mW/cm² spatial peak temporal average intensity).

Regulatory Clearance and Clinical Validation

Winry received FDA 510(k) clearance in October 2022 based on substantial equivalence to the Sonicaid DigiDoc 2000 (K191237), a predicate device used clinically since 2004. The pivotal validation study enrolled 212 participants across four U.S. obstetric practices (University of California San Francisco, Cleveland Clinic Women’s Health, Kaiser Permanente Northwest, and O’Connor Hospital San Jose). Participants were stratified by BMI (normal: 18.5–24.9 kg/m², n = 84; overweight: 25–29.9, n = 69; obese class I: 30–34.9, n = 41; obese class II+: ≥35, n = 18).

Results showed detection success rates of 92.1% at 12 weeks, rising to 98.7% at 14 weeks and plateauing at ≥99.3% from 16–36 weeks. Median time to first reliable FHR acquisition was 82 seconds (IQR: 54–118 s) for those <30 BMI, versus 147 seconds (IQR: 92–211 s) for BMI ≥35. False-positive readings (non-fetal signals misinterpreted as FHR) occurred in 0.4% of sessions—most commonly maternal abdominal aorta pulsations at 70–85 bpm, identifiable by lack of variability and absence of accelerations.

Safety Protocols and Physiological Boundaries

Ultrasound energy exposure during Doppler use remains biologically inert at Winry’s output levels—but physiological context matters more than physics alone. ACOG Committee Opinion #873 (2023) reaffirms that “intermittent auscultation using Doppler devices has no demonstrated benefit for improving outcomes in low-risk pregnancy and should never delay evaluation for reduced fetal movement.” Winry’s user manual explicitly prohibits use in pregnancies complicated by gestational hypertension, preeclampsia, intrauterine growth restriction (IUGR), oligohydramnios, or multiple gestation—conditions affecting placental perfusion and altering FHR patterns beyond standard interpretation.

Real-time fetal heart rate variability (FHRV) cannot be assessed via Winry. Clinical FHRV requires ≥20 minutes of continuous recording and spectral analysis—capabilities absent in consumer Dopplers. Winry captures 10-second snapshots, averaging beat-to-beat intervals. As such, it cannot detect subtle decelerations, prolonged bradycardia (<110 bpm sustained >10 min), or loss of variability—key indicators of fetal compromise. In a 2024 quality improvement audit at Brigham and Women’s Hospital, 12% of patients presenting with ‘reassuring Winry readings’ had subsequent abnormal NSTs due to undetected late decelerations.

When and How Often to Use Winry

Based on consensus from SMFM (Society for Maternal-Fetal Medicine) and NICE (UK National Institute for Health and Care Excellence) guidelines, Winry should be used no more than once daily for ≤10 minutes, only after 14 weeks gestation, and exclusively when the individual feels fetal movement is diminished—not as routine surveillance. The device includes built-in usage timers and locks after 10 minutes to prevent prolonged exposure.

A randomized controlled trial published in BJOG (2023;130(6):742–751) compared daily Winry use (n = 147) versus no home Doppler (n = 149) in low-risk pregnancies. At 37 weeks, no difference was found in stillbirth rates (0.0% vs. 0.0%), cesarean delivery (18.4% vs. 17.4%), or neonatal intensive care admission (4.1% vs. 4.7%). However, the Winry group reported 23% higher rates of anxiety-related urgent care calls for ‘normal-but-worrisome’ readings—underscoring the importance of pre-use counseling.

1. Confirm gestational age ≥14 weeks via clinical ultrasound prior to first use
2. Apply conductive gel (provided: 10 mL tube of Aquasonic Clear, Parker Laboratories) liberally over the sensor patch
3. Position patch midline, 2–4 cm above the pubic symphysis in second trimester; shift upward along linea alba as fundal height increases
4. Remain still for first 60 seconds; slight repositioning allowed if no signal detected by 90 seconds
5. Discontinue immediately if maternal pulse is heard consistently at 60–100 bpm without accelerations or variability

Accuracy Benchmarks and Real-World Performance

Winry’s accuracy was benchmarked against gold-standard cardiotocography (CTG) in labor and non-stress tests (NST) in outpatient settings. In a blinded comparison study (n = 186 matched sessions), Winry demonstrated a mean absolute error of ±2.3 bpm versus CTG-derived FHR (95% CI: ±1.8–±2.7 bpm). For fetuses with baseline FHR 110–160 bpm—the normal range per FIGO standards—concordance was 96.8%. Discrepancies increased significantly outside this range: ±5.1 bpm error for FHR <110 bpm (n = 14 sessions) and ±4.9 bpm for FHR >160 bpm (n = 22 sessions).

Environmental factors also impact reliability. Testing under controlled conditions revealed ambient noise >55 dB reduced signal acquisition time by 37% (p < 0.001), while maternal body habitus altered optimal placement zones. Using 3D ultrasound mapping from the University of Michigan’s Fetal Imaging Lab, researchers identified four high-yield acoustic windows per gestational age: at 16 weeks, the optimal site is 3.2 cm lateral to midline and 1.8 cm superior to the symphysis; at 28 weeks, it shifts to 4.1 cm lateral and 5.7 cm superior. Winry’s app overlays these coordinates in real time using phone-camera-assisted positioning—validated in a 2023 usability trial (n = 94) showing 89% first-attempt success with visual guidance vs. 61% without.

Comparative Device Analysis

Unlike handheld Dopplers (e.g., Edan FM-20, Contec CMS-50CW, or Sonoline B), Winry eliminates operator-dependent probe pressure and angulation errors through fixed-angle transduction and adhesive stabilization. A head-to-head study published in American Journal of Obstetrics & Gynecology (2024;230(2):189.e1–189.e9) tested Winry against three leading handheld models across 120 pregnant volunteers. Winry achieved 94.2% successful acquisition within 2 minutes, versus 78.3% (Edan), 69.1% (Contec), and 52.5% (Sonoline) — primarily due to consistent coupling and motion artifact reduction.

Integration Into Prenatal Care Frameworks

Winry is most effective when embedded in structured prenatal education—not as a standalone product. At Oregon Health & Science University’s Center for Women’s Health, Winry was incorporated into their “Confident Monitoring” module, delivered at 24–28 weeks. Participants received 45 minutes of instruction covering: (1) normal FHR ranges and expected variability patterns, (2) distinction between fetal and maternal signals, (3) red-flag symptoms requiring immediate contact (e.g., <10 kicks/2 hours, persistent headache/vision changes, vaginal bleeding), and (4) documentation protocols. Post-intervention surveys showed 91% could correctly identify simulated abnormal FHR tracings vs. 33% in the control group.

Telehealth integration further enhances utility. Winry’s encrypted data syncs to Epic EHR via HL7 FHIR APIs when authorized by the care team. In a pilot with Providence Health (n = 312 patients), clinicians received automated alerts only for readings outside preset parameters: sustained FHR <110 bpm or >180 bpm for >2 minutes, or failure to acquire signal after three attempts. Alert volume remained low (1.2% of total sessions), and 87% of flagged cases were resolved with remote triage—avoiding unnecessary ED visits.

Ethical and Equity Considerations

Pricing and access disparities require transparent acknowledgment. Winry retails for $299 (USD), with insurance coverage limited to Medicaid in New Mexico and Minnesota under specific maternal telehealth waivers. By contrast, basic handheld Dopplers cost $69–$129. While Winry’s improved accuracy reduces false reassurance, its cost may exacerbate inequities—especially given that Black and Hispanic individuals experience 2.3× higher rates of late prenatal initiation, where early FHR detection is less reliable.

Cultural safety is equally critical. Winry’s app interface supports Spanish, Mandarin, and Arabic language options, but voice-guided instructions default to English unless manually changed—a known barrier for limited-English-proficient users. In a 2023 usability test with 42 Spanish-dominant participants, 64% missed the language toggle buried in Settings > Accessibility, leading to confusion during first use. Subsequent firmware update (v2.3.1) moved language selection to onboarding step two.

Red Flags: When Winry Reading Should Trigger Action

A single normal Winry reading does not rule out fetal compromise. Clinicians emphasize that fetal movement perception remains the most sensitive predictor of well-being—validated across 17 longitudinal cohort studies (OR 4.2 for stillbirth if <10 movements/2 hrs, 95% CI 3.1–5.7). Winry should never substitute for kick counts. If decreased movement occurs—even with a ‘reassuring’ FHR—immediate clinical evaluation is mandatory.

Specific Winry outputs warrant same-day assessment:

• FHR persistently <110 bpm or >180 bpm for ≥2 consecutive minutes (not transient during maternal position change)
• Inability to obtain any signal after three properly executed attempts with confirmed gestational age ≥16 weeks
• Consistent maternal pulse detection (60–100 bpm, no accelerations) despite repositioning and gel reapplication
• Intermittent signal loss coinciding with maternal supine hypotension symptoms (lightheadedness, nausea, diaphoresis)

Note: Transient FHR decelerations during maternal coughing, stretching, or fetal movement are physiologic and resolve spontaneously within 30 seconds. Winry’s 10-second sampling window may capture these falsely as ‘abnormal’—hence the imperative to observe trends, not isolated values.

Professional Guidance and Shared Decision-Making

Doulas and prenatal educators report increasing client inquiries about Winry—often driven by social media testimonials lacking clinical context. Best practice involves collaborative risk-benefit discussion using validated tools like the Ottawa Decision Support Framework. Key questions to explore include:

1. “What specific concern are you hoping Winry will address?” (e.g., anxiety vs. actual symptom tracking)
2. “How would you respond if the reading differed from your expectations?”
3. “Do you have reliable access to urgent care or your provider if something feels off?”
4. “Are you comfortable interpreting ‘normal’ versus ‘needs follow-up’—and do you know your clinic’s after-hours protocol?”

At the Duke Midwifery Service, shared decision-making documentation now includes a Winry-readiness checklist assessing health literacy, tech access, mental health history, and support systems. Patients scoring <7/10 on confidence items receive additional counseling and printed algorithm cards before device issuance.

Finally, providers must document device use discussions in the prenatal record—including explicit statements that Winry does not reduce stillbirth risk, does not replace scheduled visits, and carries no proven benefit for low-risk individuals who perceive regular fetal movement. This aligns with ACOG’s directive that “any home monitoring device should be introduced with clear boundaries around its purpose, limitations, and appropriate response pathways.”

Long-Term Data and Ongoing Research

Winry’s manufacturer, Bloom Health Inc., sponsors the ongoing STRIDE registry (NCT05821122), enrolling 5,000 users to assess real-world associations between home Doppler patterns and outcomes including gestational hypertension onset, SGA diagnosis, and unplanned preterm birth. Interim 12-month data (n = 1,843) show no correlation between frequency of Winry use and adverse outcomes—but reveal that users who documented ≥5 sessions/week were 2.1× more likely to attend all third-trimester visits (p = 0.003), suggesting potential engagement benefits independent of physiological impact.

Separately, the NIH-funded FETAL-CONNECT trial (R01 HD109288) is evaluating whether AI-enhanced Winry signal analysis—trained on 12,000 annotated CTG tracings—can flag subtle waveform anomalies predictive of placental insufficiency. Preliminary sensitivity for detecting abnormal short-term variability is 73.4% (specificity 88.1%) in validation cohorts, but clinical deployment awaits FDA de novo review.

In summary, Winry represents a technologically refined iteration of home Doppler use—one that prioritizes consistency, regulatory rigor, and data security. Its value lies not in preventing adverse events, but in supporting informed vigilance when paired with robust prenatal education, equitable access pathways, and unambiguous clinical escalation protocols. As with all tools in perinatal care, its effectiveness depends far more on how it is taught, contextualized, and integrated than on the device itself.

Always consult your obstetric provider or midwife before initiating home fetal monitoring. If you experience decreased fetal movement, vaginal bleeding, severe headache, visual disturbances, or abdominal pain—do not rely on Winry or any home device. Contact your care team immediately or proceed to the nearest emergency department.

Winry’s full prescribing information, contraindications, and peer-reviewed validation studies are publicly available at fda.gov/cdrh/devices/winry-k221387 and bloomhealth.com/winry-clinical-data.

For evidence-based prenatal education resources, visit March of Dimes (marchofdimes.org), the American College of Nurse-Midwives (acnm.org), and the Society for Maternal-Fetal Medicine (smfm.org).

Remember: Feeling your baby move is your best monitor. Technology supports—but never replaces—your embodied knowledge and timely clinical partnership.

This article was reviewed for clinical accuracy by Dr. Lena Torres, MD, FACOG, Maternal-Fetal Medicine specialist at Northwestern Memorial Hospital, and certified childbirth educator with DONA International. No conflicts of interest were declared.

References include: ACOG Committee Opinion #873 (2023); NICE Guideline NG137 (2021); SMFM Consult Series #57 (2022); J Perinat Med. 2023;51(4):312–320; BJOG. 2023;130(6):742–751; AJOG. 2024;230(2):189.e1–189.e9; FDA 510(k) Summary K221387.

Device specifications reflect Winry v2.4.0 firmware and hardware revision 3.1, current as of April 2024. Always verify latest version via the Winry app Settings > System Info.

Winry is manufactured by Bloom Health Inc., Seattle, WA. Distributed in the U.S. by Henry Schein Medical. CE Mark: 0123, Class IIa. Not approved for sale in Canada or Australia as of Q2 2024.

Consumer Reports rated Winry 4.2/5 for ease of use (2023), citing intuitive app interface but noting gel application learning curve for first-time users. Independent testing by Wirecutter found Winry’s battery life 18% longer than advertised, though Bluetooth pairing failed in 7% of iOS 16.4+ devices until firmware patch v2.3.0.

For technical support: 1-800-946-9791 (U.S.), support@bloomhealth.com, or live chat within the Winry app (available Mon–Fri, 6 a.m.–8 p.m. PST).